Advertisement
GSK vs PFE
Which Stock Would AI Choose? GSK plc (GSK) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- GSK is riding momentum in specialty medicines and vaccines, with recent quarters beating expectations and revenue growth guided toward the upper end of its range.
- PFE has staged a notable rebound, gaining roughly 18–25% year to date on a rotation into defensive, high-yield healthcare names.
- The two stocks diverge sharply on income appeal: Pfizer offers a dividend yield near 5.8%, while GSK's sits closer to 3.5% with a lower payout ratio.
- Both face patent cliffs, but GSK's pipeline momentum is more recently visible, while Pfizer is rebuilding through acquisitions in oncology and obesity.
- Analyst sentiment is mixed on both names, though Pfizer's consensus skews toward outperform while GSK draws a wider spread of buy and sell ratings.
- For more detail on these tickers, explore GSK Major News and GSK Today's Price Move, as well as PFE Major News and PFE Today's Price Move.
- For a data-driven view of how automated strategies are positioned, explore the Trending AI Robots.
Introduction
GSK plc and Pfizer Inc. are two of the world's largest pharmaceutical companies, yet their investment profiles have diverged meaningfully over the past year. GSK, the London-listed British biopharmaceutical group, has leaned into vaccines, HIV, and oncology, while PFE, the U.S.-based drugmaker, has spent the period repositioning away from pandemic-era revenue toward oncology and obesity. For investors weighing a high-yield turnaround story against a steadier, dividend-backed pipeline narrative, this stock comparison offers a useful lens on relative performance, market positioning, and risk. It is particularly relevant to income-focused investors and those tracking sector rotation within defensive healthcare names.
GSK Overview and Recent Performance
GSK plc is a British biopharmaceutical company focused on vaccines, specialty medicines, and general medicines. In recent weeks, its underlying results have outpaced expectations, with specialty medicines — led by oncology and HIV — and vaccines doing the heavy lifting, while the older respiratory franchise softened. Management reaffirmed full-year guidance and indicated revenue growth should now track toward the upper end of its range. A newly announced multi-year efficiency programme is designed to simplify the organization and free capital for late-stage development, a priority given upcoming patent expiries on several HIV medicines later this decade. The company has also pressed an acquisition-led push into oncology and recently secured U.S. Food and Drug Administration (FDA) approval for a first-of-its-kind hepatitis B therapy, adding a tangible pipeline catalyst. The shares carry a dividend yield around 3.5% with a modest payout ratio near 39%, reinforcing the income story.
PFE Overview and Recent Performance
Pfizer Inc. is a U.S.-based pharmaceutical giant spanning primary care, specialty care, and oncology, with roughly 59% of sales derived from the United States. After years of underperformance tied to fading COVID-19 product revenue, the stock has reawakened in recent months, gaining roughly 18–25% year to date on a broader rotation into higher-yielding defensive healthcare names. Pfizer has pursued a reset through acquisitions, including a bidding-war win for obesity specialist Metsera and a licensing agreement with Enodia Therapeutics, while advancing an obesity candidate targeting a potential 2028 approval. The dividend remains central to the bull case, with a forward yield near 5.8% and a 352nd consecutive quarterly payout recently declared. The shares trade at a steep trailing price-to-earnings (P/E) ratio but a much lower forward multiple near 10 times, reflecting restructuring charges and the market's anticipation of earnings recovery.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that trade thousands of different tickers, each built around its own strategy, timeframe, risk profile, and performance record. Because market conditions shift constantly, not every bot is suited to every environment — which is why Tickeron curates only the strongest, most relevant performers into its Trending AI Robots section. This selection highlights bots whose recent statistics, win rates, and drawdown characteristics align with current market dynamics, offering traders a filtered view rather than an overwhelming list. Whether a bot focuses on momentum, mean reversion, or swing trading, each presents distinct performance metrics for evaluation. Explore the Trending AI Robots page to review the strategies currently demonstrating the strongest alignment with today's conditions.
Head-to-Head Comparison
The two companies diverge on growth drivers and market positioning. GSK is benefiting from visible near-term pipeline execution — including a recent regulatory approval — and a disciplined cost program, but it also carries analyst skepticism around valuation and future patent losses. PFE offers a substantially higher dividend yield and a discounted forward multiple, yet it faces a concentrated patent cliff across Eliquis, Xeljanz, Ibrance, and Xtandi over the next few years and depends on execution in obesity and oncology to offset those losses. On balance sheets, Pfizer has taken on meaningful debt through acquisitions, while GSK's efficiency drive and lower payout ratio signal a more defensive capital posture. In terms of sentiment, Pfizer's consensus leans toward outperform with insider buying, whereas GSK's analyst community is more split between buy, hold, and sell ratings.
Tickeron AI Verdict
Based on observable trend consistency, stability, and near-term catalysts, Tickeron's AI would likely tilt toward PFE in the current environment. The stock's recent momentum is supported by a durable rotation into high-yield healthcare names, a discounted forward valuation, and a concrete pipeline of late-stage catalysts across oncology and obesity. That said, GSK presents a steadier, lower-yield profile with strong specialty-medicine momentum and a newly approved product that could sustain its trend over a longer horizon. The verdict is probabilistic rather than definitive: the AI would favor Pfizer's higher-risk, higher-reward momentum now, while recognizing that GSK's stability may appeal more to investors prioritizing consistency over turnaround upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and PFE is a Hold.
GSK's RSI Indicator recovers from oversold territory
The RSI Oscillator for GSK moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 17 of the 23 cases the stock moved higher. This puts the odds of a move higher at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 58 cases where GSK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In 37 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
The Moving Average Convergence Divergence Histogram (MACD) for GSK turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 22 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.
GSK moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GSK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.578) is normal, around the industry mean (-1.619). P/E Ratio (20.488) is within average values for comparable stocks, (21.766). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.036) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
PFE's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PFE turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 25 of 43 cases over the following month. The odds of a continued upward trend are 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 152 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 87 of 196 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 11 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 46 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.007) is normal, around the industry mean (-1.619). P/E Ratio (38.961) is within average values for comparable stocks, (21.766). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.057) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
GSK | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 40 | 100 | |
SMR RATING 1..100 | 34 | 83 | |
PRICE GROWTH RATING 1..100 | 50 | 15 | |
P/E GROWTH RATING 1..100 | 8 | 3 | |
SEASONALITY SCORE 1..100 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (80) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that GSK’s stock grew similarly to PFE’s over the last 12 months.
GSK's Profit vs Risk Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that GSK’s stock grew somewhat faster than PFE’s over the last 12 months.
GSK's SMR Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (83). This means that GSK’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (50). This means that PFE’s stock grew somewhat faster than GSK’s over the last 12 months.
PFE's P/E Growth Rating (3) in the Pharmaceuticals Major industry is in the same range as GSK (8). This means that PFE’s stock grew similarly to GSK’s over the last 12 months.
| GSK | PFE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | 1 day ago 42% |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 50% |
| Momentum ODDS (%) | 1 day ago 48% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 47% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 53% |
| TrendMonth ODDS (%) | 1 day ago 59% | 1 day ago 49% |
| Advances ODDS (%) | 19 days ago 63% | 2 days ago 54% |
| Declines ODDS (%) | 1 day ago 55% | 9 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 44% | N/A |
| Aroon ODDS (%) | 1 day ago 43% | 1 day ago 44% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- GSK’s TA Score: 3 bullish, 7 bearish.
- PFE’s TA Score: 3 bullish, 4 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -4.40% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.67% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.32%. For the same industry, the average monthly price growth was -0.80%, and the average quarterly price growth was +3.89%.
Reported Earning Dates
GSK is expected to report earnings on Feb 03, 2027.
PFE is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.32% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.